ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3023% above fair value
$1382.75−32.80 (-2.32%)
Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%
Eli Lilly net income
Net income is the profit left for shareholders after every expense, interest and tax.
Eli Lilly's net income for the twelve months ending Sep 30, 2026 was $27.58B, up 49.8% year over year. For fiscal 2025 it was $20.64B, up 94.9% from the year before. Over ten years it grew 24.0% a year on average. The highest annual figure on record is $20.64B in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.64B | +94.9% |
| FY2024 | Dec 31, 2024 | $10.59B | +102.1% |
| FY2023 | Dec 31, 2023 | $5.24B | -16.1% |
| FY2022 | Dec 31, 2022 | $6.24B | +11.9% |
| FY2021 | Dec 31, 2021 | $5.58B | -9.9% |
| FY2020 | Dec 31, 2020 | $6.19B | -25.5% |
| FY2019 | Dec 31, 2019 | $8.32B | +157.4% |
| FY2018 | Dec 31, 2018 | $3.23B | – |
| FY2017 | Dec 31, 2017 | -$204.10M | -107.5% |
| FY2016 | Dec 31, 2016 | $2.74B | +13.7% |
| FY2015 | Dec 31, 2015 | $2.41B | +0.7% |
| FY2014 | Dec 31, 2014 | $2.39B | -49.0% |
| FY2013 | Dec 31, 2013 | $4.68B | +14.6% |
| FY2012 | Dec 31, 2012 | $4.09B | -6.0% |
| FY2011 | Dec 31, 2011 | $4.35B | -14.2% |
| FY2010 | Dec 31, 2010 | $5.07B | +17.1% |
| FY2009 | Dec 31, 2009 | $4.33B | – |
| FY2008 | Dec 31, 2008 | -$2.07B | -170.2% |
| FY2007 | Dec 31, 2007 | $2.95B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.45B | +15.5% |
| Q2 FY2026 | Jun 30, 2026 | $7.10B | +25.3% |
| Q1 FY2026 | Mar 31, 2026 | $7.40B | +168.1% |
| Q4 FY2025 | Dec 31, 2025 | $6.64B | +50.5% |
| Q3 FY2025 | Sep 30, 2025 | $5.58B | +475.4% |
| Q2 FY2025 | Jun 30, 2025 | $5.66B | +90.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.76B | +23.0% |
| Q4 FY2024 | Dec 31, 2024 | $4.41B | +101.4% |
| Q3 FY2024 | Sep 30, 2024 | $970.30M | – |
| Q2 FY2024 | Jun 30, 2024 | $2.97B | +68.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.24B | +66.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.19B | +13.0% |
| Q3 FY2023 | Sep 30, 2023 | -$57.40M | -104.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.76B | +85.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.34B | -29.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.94B | +12.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.45B | +30.8% |
| Q2 FY2022 | Jun 30, 2022 | $952.50M | -31.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.90B | +40.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.73B | -18.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.11B | -8.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.39B | -1.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.36B | -6.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.12B | +41.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.21B | -3.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.41B | +6.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.46B | -65.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.50B | +33.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.25B | +9.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.33B | – |
| Q1 FY2019 | Mar 31, 2019 | $4.24B | +248.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.13B | – |
| Q3 FY2018 | Sep 30, 2018 | $1.15B | +106.9% |
| Q2 FY2018 | Jun 30, 2018 | -$259.90M | -125.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.22B | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.66B | -314.7% |
| Q3 FY2017 | Sep 30, 2017 | $555.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.01B | – |
| Q1 FY2017 | Mar 31, 2017 | -$110.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $771.80M | – |
See a number that looks wrong?